Abstracts tagged "Drug toxicity"

Abstract Number: 1718 • ACR Convergence 2025
Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
Kevin Sheng-Kai Ma¹, Dominique Feterman Jimenez², You Wu³, Jenna Thomason³, Jean Liew⁴ and Namrata Singh⁵, ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²University of Washington, Seattle, ³University of Washington, Seattle, WA, ⁴Boston University, Boston, MA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their safety profile in patients with pre-existing autoimmune diseases, such as systemic lupus erythematosus (SLE),…
Abstract Number: 0655 • ACR Convergence 2025
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Eric Roberts¹, gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: Hypertension was a common adverse event in RCTs testing voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN). In these…
Abstract Number: 1604 • ACR Convergence 2025
Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study
Lucas Khellaf¹, Raphaele Seror², caterina ricordi³, stephanie chhun⁴, audes gleizes⁴, hervé lobbes⁵, clara pouchelon⁶, marie Charlotte Besse⁷, Jean-Emmanuel Kahn⁸, sabine revuz⁹, Marina Cumin¹⁰, Dimitri Titeca-Beauport¹¹, Matthias Papo⁶, Philippe Rémy⁶, marie Desprets¹², florian garo¹³, Charles Ronsin¹⁴, Salima Hacein-Bey-Abina⁶, Amélie Servettaz¹⁵, Cacoub Patrice¹⁶, Xavier Puéchal¹⁷ and Benjamin Terrier¹⁸, ¹AP-HP, Paris, ²Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ³Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ⁴APHP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ⁶APHP, Paris, France, ⁷CHU Tours, Tours, France, ⁸Ambroise Paré hospital, Boulogne, France, ⁹CHU de la Réunion, Réunion, France, ¹⁰Centre hospitalier de Libourne, Libourne, France, ¹¹CHU Amiens, Amiens, France, ¹²CH Chôlet, Cholet, France, ¹³CHU Nîmes, Nîmes, France, ¹⁴CHU Nantes, Nantes, France, ¹⁵Internal Medicine, CHU Reims, Reims, France, ¹⁶Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹⁸Cochin Hospital, Paris, France
Background/Purpose: Small vessel vasculitis mainly includes ANCA-associated vasculitis (AAV) and cryoglobulinemic vasculitis (CV), leading to significant organ damage. Rituximab (RTX), an anti-CD20 monoclonal antibody, has…
Abstract Number: 0352 • ACR Convergence 2025
Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures
Marshall Weber¹, William Obremskey², Jared Huling³, Nitya Shah³, Emily Budde⁴, Zhiping Huo⁴, Reside Jacob⁴, Brinda Basida¹, Colton Hoffer¹, Binni Makkar⁵ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²Vanderbilt University, Nashville, TN, ³University of Minnesota School of Public Health, Minneapolis, MN, ⁴Center of Innovation for Complex Chronic Healthcare, Washington DC, DC, ⁵University of Kentucky, Lexington, KY
Background/Purpose: Atypical femoral fractures (AFFs) are a rare complication of bisphosphonate use and a major reason that drug holidays are recommended following bisphosphonate use. However,…
Abstract Number: 1593 • ACR Convergence 2025
Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients
Blaise Pasquiers¹, Benoit Blanchet², Xavier Puéchal³, Xavier Declèves¹, Pascal Cohen⁴, Claire Goulvestre¹, Marion Casadevall¹, Ines Benhabiles¹, Michel Vidal¹, David Ternant¹, Benjamin Terrier⁵ and Alicja Puszkiel⁶, ¹Hopital Cochin, Paris, France, ²National Referral Centre for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Cochin Hospital, Paris, France, ⁶Cochin Hospital, Paris
Background/Purpose: For the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), rituximab (RTX) may be given as a 4-dose regimen (375 mg/m2 weekly for 4…
Abstract Number: 0230 • ACR Convergence 2025
An Epic journey – Therapeutic Drug Monitoring at an Academic Center
Puja Khanna¹ and Michael Rice², ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Gastroenterology, University of Michigan, Ann Arbor, MI
Background/Purpose: Non-oncologic use of immunomodulatory agents is increasing. These drugs have a narrow, patient-specific therapeutic index, making therapeutic drug monitoring essential for safe prescribing. However,…
Abstract Number: 2658 • ACR Convergence 2025
Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Hsin-Hua Chen and Wen-Cheng Chao, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity due to their beneficial metabolic effects. However,…
Abstract Number: 1517 • ACR Convergence 2025
The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
Aijing Liu¹, Fei Chang² and Qiuhong Xu¹, ¹Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), ²Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic)
Background/Purpose: Lupus nephritis (LN), affects 30%-50% of systemic lupus erythematosus (SLE) patients, a major contributor to SLE-related mortality. Telitacicept, an innovative recombinant fusion protein, disrupts…
Abstract Number: 0045 • ACR Convergence 2025
Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
Thomas Riley¹, Bryant England², Austin Wheeler², Punyasha Roul³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Mitchell Lazar¹, Wenxiang Hu¹⁴, Michael Levin¹⁵, Scott Damrauer¹⁵, Rui Xiao¹⁶, Tate Johnson², Ted Mikuls², Joshua Baker¹ and Michael George¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴Guangzhou National Laboratory, Guangzhou, China (People's Republic), ¹⁵University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ¹⁶Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Previous studies identified single nucleotide polymorphisms (SNPs) that affect hepatocyte and adipocyte response to glucocorticoids (GCs). We aimed to determine if these candidate SNPs…
Abstract Number: 2507 • ACR Convergence 2025
Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)
Camille Mettler¹, Laurent Chouchana² and Benjamin Terrier³, ¹Département de Médecine interne, Hôpital Bichat-Claude-Bernard, Paris, France, ²Département de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Cochin, Paris, France, ³Cochin Hospital, Paris, France
Background/Purpose: Avacopan, an oral C5aR antagonist, is approved for the treatment of ANCA-associated vasculitis (AAV) as a steroid-sparing alternative. While clinical trials demonstrated a positive…
Abstract Number: 1116 • ACR Convergence 2025
Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
Sarah Sun¹, Cathryn Lee² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chicago, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) used for cancer therapy can have varied toxicities among which pneumonitis (ICI-pneumonitis) is a rare (< 5%) but often fatal…
Abstract Number: 2276 • ACR Convergence 2025
Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
Jennifer Hanberg¹, David Cheng², Xuan Wang³, Rahul Sangar⁴, Yuk-Lam Ho⁴, Lauren Costa⁴, Rachael Matty⁴, Candace Feldman¹, Tate Johnson⁵, Joshua Baker⁶, Bryant England⁵, J. Michael Gaziano¹, Kelly Cho⁷, James O'Dell⁵, Grant Cannon⁸, Paul Monach⁴, Ted Mikuls⁵, Tianxi Cai⁷ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³University of Utah, Salt Lake City, UT, ⁴VA Boston Healthcare System, Boston, MA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Harvard Medical School, Boston, MA, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are often avoided when treating rheumatoid arthritis (RA) patients with decompensated heart failure (HF), based on increased rates of…
Abstract Number: 1112 • ACR Convergence 2025
Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
Manush Sondhi¹, Namrata Singh², Julie Carkin¹ and Grant Hughes³, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³University of Washington, Lynnwood, WA
Background/Purpose: The cardiovascular risks associated with osteoporosis medications remain incompletely understood. Previous studies suggest that romosozumab (ROM) is most strongly associated with major adverse cardiovascular…
Abstract Number: 2269 • ACR Convergence 2025
Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
Daniel Campos-Martin¹, Nerea Alcorta-Lorenzo², César Antonio Egües Dubuc², Luis Maria Lopez-Dominguez³, Lucia Otero⁴, Fernando Sánchez-Alonso⁵ and Joaquin Maria Belzunegui-Otano⁶, ¹Rheumatology Department, Donostia University Hospital, San Sebastian-Donostia, Pais Vasco, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ⁴Spanish Society of Rheumatology, Madrid, Spain, ⁵Sociedad Española de Reumatología, Madrid, Spain, ⁶Rheumatology Department, Donostia University Hospital., San Sebastian-Donostia, Spain
Background/Purpose: Baricitinib, a selective JAK1/JAK2 inhibitor, has demonstrated efficacy in rheumatoid arthritis (RA). In patients with stable disease control for at least six months, reducing…
Abstract Number: 1102 • ACR Convergence 2025
Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Julia Barasch¹, Nilasha Ghosh², Deanna Jannat-Khah³, Kyle Ge⁴, Jeffrey Curtis⁵ and Anne R. Bass³, ¹NYP- Weill Cornell, New York, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: New onset inflammatory arthritis (IA) is reported in 6% of patients who receive immune checkpoint inhibitors (ICI). We previously developed an administrative claims-based algorithm…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].